ES2620740T3 - Epítopos de células T CD4 de PAP promiscuos - Google Patents

Epítopos de células T CD4 de PAP promiscuos Download PDF

Info

Publication number
ES2620740T3
ES2620740T3 ES07840861.4T ES07840861T ES2620740T3 ES 2620740 T3 ES2620740 T3 ES 2620740T3 ES 07840861 T ES07840861 T ES 07840861T ES 2620740 T3 ES2620740 T3 ES 2620740T3
Authority
ES
Spain
Prior art keywords
presenting cells
antigen presenting
expressing antigen
cell epitopes
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07840861.4T
Other languages
English (en)
Inventor
Jami B. Wollan
Lori A. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Pharmaceuticals LLC
Original Assignee
Dendreon Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Pharmaceuticals LLC filed Critical Dendreon Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2620740T3 publication Critical patent/ES2620740T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un peptido aislado que consiste en 15 a 18 aminoacidos y que comprende la secuencia de aminoacidos de la SEQ ID NO: 1, en donde el peptido activa las celulas T cuando es presentado por celulas presentadoras de antigeno que expresan HLA-DR1, celulas presentadoras de antigeno que expresan DR4, celulas presentadoras de antigeno que expresan DR7, celulas presentadoras de antigeno que expresan DR8, celulas presentadoras de antigeno que expresan DR11, celulas presentadoras de antigeno que expresan DR12, celulas presentadoras de antigeno que expresan DR13, celulas presentadoras de antigeno que expresan DR14 y celulas presentadoras de antigeno que expresan DR15.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
ES07840861.4T 2006-08-11 2007-08-10 Epítopos de células T CD4 de PAP promiscuos Active ES2620740T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US836653 2004-04-29
US83705306P 2006-08-11 2006-08-11
US837053P 2006-08-11
US11/836,653 US8361479B2 (en) 2006-08-11 2007-08-09 Promiscuous PAP CD4 T cell epitopes
PCT/US2007/075704 WO2008022030A2 (en) 2006-08-11 2007-08-10 Promiscuous pap cd4 t cell epitopes

Publications (1)

Publication Number Publication Date
ES2620740T3 true ES2620740T3 (es) 2017-06-29

Family

ID=39082999

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07840861.4T Active ES2620740T3 (es) 2006-08-11 2007-08-10 Epítopos de células T CD4 de PAP promiscuos

Country Status (7)

Country Link
US (2) US8361479B2 (es)
EP (1) EP2056859B1 (es)
JP (1) JP5189094B2 (es)
CA (1) CA2660064C (es)
ES (1) ES2620740T3 (es)
PL (1) PL2056859T3 (es)
WO (1) WO2008022030A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110127637A (ko) * 2008-12-22 2011-11-25 칠드런스리서치인스티튜트 패혈증 검출 방법
WO2010119307A1 (en) 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
FR3000263B1 (fr) * 2012-12-21 2015-03-06 Ingenico Sa Detection d'un dispositif transactionnel
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
CN110079539B (zh) * 2018-01-25 2022-07-01 上海惠盾因泰生物科技有限公司 前列腺酸性磷酸酶/粒-巨噬细胞集落刺激因子制备方法
IT202000013243A1 (it) 2020-06-04 2021-12-04 Novamont Spa Processo per la purificazione di una miscela di dioli

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552534A (en) 1991-08-22 1996-09-03 The Trustees Of The University Of Pennsylvania Non-Peptide peptidomimetics
US5550251A (en) 1991-12-12 1996-08-27 The Trustees Of The University Of Pennsylvania Alicyclic peptidomimetics
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
JP2003521245A (ja) * 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
EP1540627A4 (en) 2002-09-20 2006-08-16 Dendreon Corp IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING MULTIPLE TO DIFFERENTIATED CANCER
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses

Also Published As

Publication number Publication date
EP2056859A4 (en) 2010-03-31
EP2056859B1 (en) 2017-01-11
PL2056859T3 (pl) 2017-07-31
JP5189094B2 (ja) 2013-04-24
US20130203163A1 (en) 2013-08-08
WO2008022030A9 (en) 2008-04-10
CA2660064A1 (en) 2008-02-21
US8647865B2 (en) 2014-02-11
CA2660064C (en) 2016-08-09
WO2008022030A3 (en) 2008-11-27
JP2010500037A (ja) 2010-01-07
US20080286293A1 (en) 2008-11-20
WO2008022030A2 (en) 2008-02-21
US8361479B2 (en) 2013-01-29
EP2056859A2 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
ES2620740T3 (es) Epítopos de células T CD4 de PAP promiscuos
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2559062T3 (es) Método para la activación de linfocitos T colaboradores y composición para su uso en el método
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
WO2005013666A3 (en) Novel translocation assay
Zou et al. Characterization of the effects of trace concentrations of graphene oxide on zebrafish larvae through proteomic and standard methods
NO20030856L (no) Membranpenetrerende peptider og anvendelse av disse
ES2634538T3 (es) Composición de detergente recubierta y proceso de fabricación
HRP20090245T1 (en) Pyy agonists and uses thereof
BRPI0506474A (pt) sistema de tecido com células tronco não diferenciadas derivadas no limbus da córnea
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
AR081354A1 (es) Metodos y reactivos par una transferencia genica eficaz y dirigida a monocitos y macrofagos
Zhou et al. Primary cultured cells as sensitive in vitro model for assessment of toxicants-comparison to hepatocytes and gill epithelia
TWD203721S (zh) 絞車(二)
Azizi et al. Activity-based sensing of S-depalmitoylases: chemical technologies and biological discovery
Held et al. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand
BRPI0518579A2 (pt) mÉtodo para aumentar a atividade de cÉlula exterminadora natural em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, uso da composiÇço que compreende Ácido lipàico, e, mÉtodo para aumentar a resposta imune em um animal
IL192484A0 (en) Luminescent transgenic non human animals, progeny, cell derivatives and uses thereof
WO2009107971A3 (ko) 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도
DE602007004110D1 (de) Hausstaubmilbenallergen
Hu et al. Surviving in an acidifying ocean: acid-base physiology and energetics of the sea urchin larva
MX2010010213A (es) Peptido parcial de lacritina.
Kaya et al. Spiroidesin, a novel lipopeptide from the cyanobacterium Anabaena spiroides that inhibits cell growth of the cyanobacterium Microcystis aeruginosa
NZ551828A (en) A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins